Molecular Target Therapy of AKT and NF-kB Signaling Pathways and Multidrug Resistance by Specific Cell Penetrating Inhibitor Peptides in HL-60 Cells |
Davoudi, Zahra
(Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Akbarzadeh, Abolfazl (Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) Rahmatiyamchi, Mohammad (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) Movassaghpour, Ali Akbar (Hematology and Oncology Research Center, Tabriz University of Medical Sciences) Alipour, Mohsen (Department of Physiology, Faculty of Medicine, Zanjan University of Medical Sciences) Nejati-Koshki, Kazem (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) Sadeghi, Zohre (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) Dariushnejad, Hassan (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) Zarghami, Nosratollah (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) |
1 | Akbarzadeh A, Samiei M, Davaran S, et al (2012). Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett, 7, 14-26. DOI ScienceOn |
2 | Akbarzadeh A, Zarghami N, Mikaeili H, et al (2012). Synthesis, characterization and in vitro evaluation of novel polymercoated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl, 5, 13-25. |
3 | Al-Bahar S, Adriana Z, Pandita R (2008). Acute myeloid leukemia as a genetic disease. Gulf J Oncolog, 3, 9-15. |
4 | Altman JK, Sassano A, Platanias LC (2011). Targeting mTOR for the treatment of AML: New agents and new directions. Oncotarge, 2, 510-7. |
5 | Bentires-Alj M, Barbu V, Fillet M, et al (2003). NF-kB transcription factor induces drug resistance through MDR1expression in cancer cells. Oncogene, 22, 90-7. DOI |
6 | Akbarzadeh A, Mikaeili H, Zarghami N, et al (2012). Preparation and in-vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymer. Int J Nanomedicine, 7, 1-16. DOI ScienceOn |
7 | Akbarzadeh A, Nejati-Koshki K, Mahmoudi Soghrati M, et al (2013). In vitro studies of NIPAAM-MAA-VP copolymercoated magnetic nanoparticles for controlled anticancer drug release. JEAS, 3, 108-15. DOI |
8 | Akbarzadeh A, Omidfar K, Ahmadin A, et al (2014). An electrochemical immunosensor for digoxin using core-shell gold coated magnetic nanoparticles as labels. Mol Biol Rep, 41, 1659-68. DOI |
9 | Akbarzadeh A, Pourhassan-Moghaddam M, Rahmati-Yamchi M, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett, 8, 485-95. DOI |
10 | Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, et al (2012). Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology, 64, 719-26. DOI ScienceOn |
11 | Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al (2013). Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev, 14, 6595-9. 과학기술학회마을 DOI ScienceOn |
12 | Norgaard JM, Hokland P (2000). Biology of multiple drug resistance in acute leukemia. Int J Hematol, 72, 290-7. |
13 | Orange JS, May MJ (2008). Cell penetrating peptide inhibitors of Nuclear Factor-kappa B. Cell Mol Life Sci, 65, 3564-91. DOI |
14 | Akbarzadeh A, Rezaei A, Nejati-Koshki K, et al (2014). Synthesis and physicochemical characterization of biodegradable star-shaped poly lactide-co-glycolide- -cyclodextrin copolymer Nanoparticles Containing Albumin, J Adv Nanoparticles, 3, 1-9. DOI |
15 | Akbarzadeh A, Rezaei-Sadabady R, Zarghami N, et al (2013). Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxytyrosol derivatives indicated by quantum chemical calculations. Soft, 2, 13-8. DOI |
16 | Park S, Chapuis N, Tamburini J, et al (2010). Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica, 95, 819-28. DOI |
17 | Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. DOI ScienceOn |
18 | Scholl C, Gilliland DG, Frohling S (2008). Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol, 35, 336-45. DOI ScienceOn |
19 | Tas SW, de Jong EC, Hajji N, et al (2005). Selective inhibition of NF-jB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur J Immuno, 35, 1164-74. DOI ScienceOn |
20 | Ta-Gan Y, Hurevich M, Klein S, et al (2011). Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J Med Chem, 54, 5154-64. DOI ScienceOn |
21 | Thanos D, Maniatis T (1995). NF-kappa B: a lesson in family values. Ce, 80, 529-32. |
22 | Tho F, Ganser A (2011). Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives. Front Med China, 4, 356-62. |
23 | Ebrahimnezhad Z, Zarghami N, Keyhani M, et al (2013). Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-Fe3O4 in T47D breast cancer cell line. Bioimpacts, 3, 67-74. |
24 | Bixby D, Talpaz M (2009). Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program, 1, 461-76. |
25 | Caceres-Cortes JR (2013). Blastic Leukaemias (AML) :A Biologist s view. Cell Biochem Biophys, 66, 13-22. DOI ScienceOn |
26 | Chuang JC, Sheu GT, Wang PC, et al (2012). Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element. Toxicol in Vitro, 26, 678-85. DOI |
27 | Harris F, Dennison SR, Singh J, et al (2013). On the selectivity and efficacy of defense peptides with respect to cancer cells. Med Res Re, 33, 190-234. DOI |
28 | Eldar-Finkelman H, Eisenstein M (2009). Peptide inhibitors targeting protein kinases. Curr Pharm Des, 15, 2463-70. DOI |
29 | Furumai R, Komatsu Y, Nishino N, et al. (2001). Potent histone deacetylase inhibitors built from trichostatin. Proc Natl Acad Sci USA, 98, 87-92. DOI ScienceOn |
30 | Grandage VL, Gale RE, et al (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NFkB, MAPkinase and p53 pathways. Leukemia, 19, 586-94. |
31 | Leith CP, Kopecky KJ, Godwin J, et al (1997). Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy ASouthwest Oncology Group Study. Blood, 89, 3323-9. |
32 | Akbarzadeh A, Samiei M, Joo SW, et al (2012). Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol, 10, 46-52. DOI |
33 | Akbarzadeh A, Ghasemali S, Nejati K, et al (2013). Study of inhibitory effect of -cyclodextrin-helenalin complex on HTERT gene expression in T47D breast cancer cell line by real time quantitative PCR (q-PCR). Asian Pac J Cancer Prev, 14, 6949-53. 과학기술학회마을 DOI ScienceOn |
34 | Akbarzadeh A, Hosseininasab S, Davaran S, et al (2014). Synthesis, characterization, and In vitro studies of PLGAPEG nanoparticles for oral Insulin delivery. Chem Biol Drug Des, 3, 1-9. |
35 | Caceres-Cortes JR (2013). Blastic leukaemias (AML): a biologist s view. Cell Biochem Biophys, 66, 13-22. DOI ScienceOn |
36 | Wang Y, Liu X, Zhang HT, et al (2007). NF-kappaB regulating expression of mdr1 gene and P-gp to reverse drug-resistance in leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 950-4. |
37 | Weisburg JH (2008). Multidrug resistance in acute myeloid leukemia: potential new therapeutics. J Nucl Med, 49, 1405-7. DOI ScienceOn |
38 | Zeng Z, Sarbassov dos D, Samudio IJ, et al (2007). Rapamycin derivatives reduce mTORC2 signaling and inhibitAKT activation inAML. Blood, 109, 3509-12. DOI ScienceOn |
39 | Levitzki A, Klein S (2010). Signal transduction therapy of cancer. Mol Aspects Med, 31, 287-329. DOI ScienceOn |
40 | Licht JD, Sternberg DW (2005). The molecular pathology of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program, 1, 137-42. |
41 | Lowenberg B, Downing J, Burnett A (1999). Acute myeloid leukaemia. N Engl J Med, 341, 1051-62. DOI ScienceOn |
42 | Miyamoto S (2011). Nuclear initiated NF- signaling: NEMO and ATM take center stage. Cell Res, 21, 116-30. DOI ScienceOn |
43 | Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8. 과학기술학회마을 DOI ScienceOn |
44 | Kumar CC, Madison V (2005). AKT crystal structure and AKTspecific inhibitors. Oncogene, 24, 7493-501. DOI ScienceOn |
45 | Birkenkamp KU, Geugien M, Schepers H, et al (2004). Constitutive NF-jB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia, 18, 103-12. DOI |
46 | Nasiri M, Zarghami N, Koshki KN, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev, 14, 3449-53. 과학기술학회마을 DOI ScienceOn |